Novo Nordisk A/S (NVO) EPS Estimated At $0.69

April 26, 2018 - By Marie Mckinney

Novo Nordisk A/S (NYSE:NVO) Logo

Analysts expect Novo Nordisk A/S (NYSE:NVO) to report $0.69 EPS on May, 2.They anticipate $0.11 EPS change or 18.97 % from last quarter’s $0.58 EPS. NVO’s profit would be $1.67B giving it 17.04 P/E if the $0.69 EPS is correct. After having $0.53 EPS previously, Novo Nordisk A/S’s analysts see 30.19 % EPS growth. The stock increased 0.30% or $0.1399 during the last trading session, reaching $47.0199. About 309,426 shares traded. Novo Nordisk A/S (NYSE:NVO) has risen 42.07% since April 26, 2017 and is uptrending. It has outperformed by 30.52% the S&P500.

Novo Nordisk A/S (NYSE:NVO) Ratings Coverage

Among 6 analysts covering Novo Nordisk A\/S Common Stock (NYSE:NVO), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Novo Nordisk A\/S Common Stock had 6 analyst reports since December 1, 2017 according to SRatingsIntel. Goldman Sachs maintained the shares of NVO in report on Friday, January 19 with “Buy” rating. The rating was upgraded by Bank of America on Wednesday, December 6 to “Buy”. The stock has “Overweight” rating by Morgan Stanley on Friday, December 1. The rating was upgraded by JP Morgan on Friday, December 29 to “Neutral”. The stock has “Hold” rating by J.P. Morgan on Friday, December 29.

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. The company has market cap of $113.59 billion. It operates in two divisions, Diabetes and Obesity Care, and Biopharmaceuticals. It has a 18.53 P/E ratio. The Diabetes and Obesity Care segment provides insulins, GLP-1 analog, and oral anti-diabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles.

Novo Nordisk A/S (NYSE:NVO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: